IMPACT STRATEGY ON A PAGE



Health and Biosecurity

		-	ROLES	
GOAL	IMPACT AREAS	IMPACT STATEMENTS	INTERNAL PROGRAMS	OTHER BUSINESS UNITS
To provide leadership and deliver measurable improvement in Australia's one-Health system: enhancing health, social, environmental and economic wellbeing in the face of increased healthcare pressures and global biosecurity threats.	Industry profitability and market access	Biosecurity threats to agriculture: By 2025 the social and economic impacts from exotic threats to Australia's animal and plant industries are reduced through improved risk assessment, prioritisation, decision support and resource allocation systems, more effective and cheaper surveillance, more effective eradication and containment responses and more resilient rural communities.		AG AAHL D61 LW OA
		Market access and trade: By 2025 market access and trade for Australia's animal and plant industries protected and grown through new technologies and approaches that break through existing barriers to trade.		AG AAHD DGI FN LW OA
	Environmental health	Preparedness and response to biosecurity threats: By 2025 the social and environmental impacts from exotic threats to Australia's natural and production environments are reduced through improved prioritisation, decision support and resource allocation systems, more cost effective surveillance, eradication and containment technologies.		AAHL D61 LW OA
		Mitigating invasive species impacts: By 2030, environmental, social and economic impacts of widespread established pests, weeds and pathogens on biodiversity and ecosystem services in natural and production landscapes reduced through improved ecological knowledge and delivery of landscape scale, socially acceptable, biologically based management options and decision support tools.		AG LW
	Health outcomes	Preparedness for infectious disease outbreaks: By 2025, Australia will be better prepared against the threat of infectious disease outbreaks through delivery of improved information on disease emergence and host-pathogen interactions and novel approaches to vector control which will either inform new science-informed regulatory and public policies or lead to improved containment and control strategies resulting in protecting our wellbeing and generating savings for the health care system.		AAHL D61 LW
	and health system — performance	Catalysing innovation in the MedTech sector: By 2030, enhance Australia's pandemic preparedness by catalysing innovation and growth in Australia's MedTech sector that is supported by our developments of innovative vaccine production systems, novel anti-virals and diagnostics that will be rapidly approved and deployed as medical countermeasures to combat infectious disease.		AG AAHI MA
	Managing Invasive	Telehealth improving remote health service access: Development of clinically and economically validated models for tele-enabled health services delivery for remote/very remote Australia, for uptake by State and Federal Health agencies resulting in a reduction of 30% of the addressable gaps in hospitalisation rates, mortality rates and/or service delivery rates between remote and urban Australia.	•	D61 FN
Combating Emerging Infectious Diseases	Species Impacts erging eHealth	Standardised data analysing health performance: Deployment of data tools in healthcare settings with the aim of standardised data being used for clinical decision support and analysing health performance. These tools will lead to a reduction in adverse events by 10% such as medication errors and an increase in the productivity of the health system by 10%.		D61
OTHER BUSINESS UNITS Agriculture	AAHL	Australia has a digitally enabled health system: Development of a sustainable health and aged care system for Australia that enables Australians to remain in their own homes longer thereby reducing the cost and detecting earlier problems associated with ageing.		D61 FN MA
 Data61 Land and Water 	 Food and Nutrition Manufacturing 	Precision medicine technologies: Deployment of precision medicine technologies targeted at improving diagnosis, reducing futile treatment, and facilitating personalised therapy. As a result, new therapies will be		D61 FN MA
Oceans and Atmospher	-	developed faster and more cost effectively, patients will have less side effects, will return to the workforce sooner, and will have an improved quality of life for longer.		